- 3
- 0
- 约6.34千字
- 约 6页
- 2017-05-05 发布于浙江
- 举报
Phentolamine La Mingzuo infants with pneumonia and heart failure treatment efficacy
PAGE \* MERGEFORMAT 6
Phentolamine La Mingzuo infants with pneumonia and heart failure treatment efficacy
[Abstract] Objective To observe phentolamine La Mingzuo governance and infant pneumonia treatment of heart failure. Methods January 1997 ~ July 2007 155 cases of children as the treatment group, in January 1993 ~ December 1994 57 cases As a control group, normal control group with antibiotics, hormones, oxygen, suction, cardiac diuretic, comprehensive treatment, the treatment group on the basis of the above plus phentolamine dose of 0.5 ~ 1 mg / (kg · times plus 5% GS 20 ml bolus, with Wualaming regular dose of phentolamine 1 / 2, 1 to 5 times a day, failure to correct stop medication at least 2 times the dose 4 mg, up to 13 times, dose of 104 mg. the treatment group compared with the control group, significant differences in heart failure corrected time (T = 3.7863, P lt;0.05, the total effective rate was no significant difference (χ2 = 2.3761, Pgt; 0.05, no difference between the average length of stay statistically significant (T = 0.7323, Pgt; 0.05. Conclusion phentolamine La Mingzuo infant pneumonia and heart failure treatment has a significant effect, it is grass-roots hospitals.
[Keywords:] phentolamine infant pneumonia and heart failure
Infant pediatric pneumonia and heart failure is most common illnesses, treatment is often less than can be life threatening, the last high mortality rate in recent years with rising levels of medicine, infant pneumonia, and decreased the proportion of heart failure and mortality were also decline, but still the key issues at the grassroots level hospital is still threatening the health of infants and young children focus on rural issues, and its mortality is still high. in our hospital from January 1997 ~ July 2007 rule applied phentolamine La Mingzuo infant pneumonia and 155 cases of heart failure, and achieved good effect, are as follows.
1 Clinical data
1.1 The diagnostic criteria for textbooks and
您可能关注的文档
- Pharmaceutical companies develop into the 'four-wheel drive' era.doc
- Pharmaceutical companies from the industry to see an extension of the convergence.doc
- Pharmaceutical companies how to deal with the procurement of Chain Drug Stores Union (PTO)-.doc
- Pharmaceutical companies are keen to engage in domestic kingdom the development of effective multi-stripping to.doc
- Pharmaceutical companies how to effectively implement the agent system.doc
- Pharmaceutical companies focus on how to choose products-.doc
- Pharmaceutical companies in the changing situation in the prominent characteristics of the benchmark.doc
- Pharmaceutical companies Extension- identify the core competencies Point.doc
- Pharmaceutical companies in the end which pin to tie bleeding-.doc
- Pharmaceutical companies Investment- How to quickly break the ice in the market-.doc
- 中国国家标准 GB/T 16172-2026建筑材料热释放速率和产烟速率试验方法.pdf
- GB/T 16172-2026建筑材料热释放速率和产烟速率试验方法.pdf
- 《GB/T 16172-2026建筑材料热释放速率和产烟速率试验方法》.pdf
- 《GB/T 14926.62-2026实验动物 猴免疫缺陷病毒检测方法》.pdf
- GB/T 14926.62-2026实验动物 猴免疫缺陷病毒检测方法.pdf
- GB/T 46917.3-2026标准语义知识库 第3部分:语义集成技术要求.pdf
- 《GB/T 46917.3-2026标准语义知识库 第3部分:语义集成技术要求》.pdf
- 中国国家标准 GB/T 46917.3-2026标准语义知识库 第3部分:语义集成技术要求.pdf
- 中国国家标准 GB/T 45305.3-2026声学 建筑构件隔声的实验室测量 第3部分:撞击声隔声测量.pdf
- GB/T 45305.3-2026声学 建筑构件隔声的实验室测量 第3部分:撞击声隔声测量.pdf
原创力文档

文档评论(0)